Arctic Bioscience ASOSL:ABS -1.85%55 Days Payable is 215.83 as of Dec. 2025, which is 3% above its 10-year median of 209.38. GuruFocus rates OSL:ABS with a GF Score™ of 55/100 and a GF Value™ of kr10.61 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 701 Biotechnology companies, Arctic Bioscience AS ranks better than 67.62% on this metric.
The historical rank and industry rank for Arctic Bioscience AS's Days Payable or its related term are showing as below:
OSL:ABS'
s Days Payable Range Over the Past 10 Years
Min: 126.31 Med: 209.38 Max: 282.69
Current: 253.53
During the past 8 years, Arctic Bioscience AS's highest Days Payable was 282.69. The lowest was 126.31. And the median was 209.38.
OSL:ABS's Days Payable is ranked better than 67.62% of 701
companies
in the Biotechnology industry
Industry Median: 112.84
vs OSL:ABS: 253.53
Arctic Bioscience AS's Days Payable
increased
from Dec. 2024 (174.65) to Dec. 2025 (215.83).
It may suggest that Arctic Bioscience ASdelayed paying its suppliers.
Arctic Bioscience AS Days Payable Related Terms
Arctic Bioscience AS Days Payable Historical Data
* Premium members only.
The historical data trend for Arctic Bioscience AS's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSL:ABS vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Arctic Bioscience AS's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arctic Bioscience AS Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arctic Bioscience AS's Days Payable distribution charts can be found below:
* The bar in red indicates where Arctic Bioscience AS's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Arctic Bioscience AS's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arctic Bioscience AS (OSL:ABS) has a Days Payable of 215.83 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Arctic Bioscience AS and its competitors. This is near median its historical median of 209.38. Over the past decade, Arctic Bioscience AS's Days Payable has ranged from 126.31 to 282.69. According to the industry distribution chart, Arctic Bioscience AS ranks #227 out of 701 companies in the Biotechnology industry, placing it in the top 32.4%.
Is Arctic Bioscience AS's Days Payable too high?
Arctic Bioscience AS's current Days Payable of 215.83 is near median its 10-year median of 209.38. Over the past 10 years, this metric has ranged from a low of 126.31 to a high of 282.69. The Biotechnology industry median Days Payable is 112.84. Arctic Bioscience AS's value of 215.83 is 91.3% above this industry median. Based on the distribution chart, Arctic Bioscience AS ranks #227 out of 701 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Arctic Bioscience AS has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Arctic Bioscience AS's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Arctic Bioscience AS ranks #227 out of 701 companies for Days Payable. This puts Arctic Bioscience AS in the upper half of its industry. The industry median Days Payable is 112.84. Arctic Bioscience AS's value of 215.83 is 91.3% above this benchmark. Historically, Arctic Bioscience AS's own Days Payable has ranged from 126.31 to 282.69 over the past decade. While the company's 10-year median is 209.38 vs. the industry median of 112.84, Arctic Bioscience AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 701 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Arctic Bioscience AS's current Days Payable of 215.83 is 91.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Arctic Bioscience AS and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arctic Bioscience AS's current Days Payable is 215.83, which is near median its own 10-year median of 209.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arctic Bioscience AS stock overvalued right now?
Based on GuruFocus' analysis, Arctic Bioscience AS (OSL:ABS) is currently considered Possible Value Trap. The stock's GF Value™ is kr10.61, compared to a current price of kr3.19 — trading 69.9% below its estimated fair value. The current Days Payable is 215.83, which is near median its 10-year median of 209.38 and 91.3% above the Biotechnology industry median of 112.84. Arctic Bioscience AS's overall GF Score™ is 55/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Arctic Bioscience AS (OSL:ABS), the current Days Payable is 215.83 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arctic Bioscience AS (OSL:ABS) Overvalued in 2026?
Based on GuruFocus' analysis, Arctic Bioscience AS stock appears to be undervalued.
The current stock price of kr3.19 is trading 69.9% below its estimated GF Value™ of kr10.61.
GuruFocus considers Arctic Bioscience AS to be Possible Value Trap.
Key valuation signals for OSL:ABS:
Days Payable: 215.83 (near median its 10-year median of 209.38)
GF Value™: kr10.61 vs. price of kr3.19 (69.9% below fair value)
Industry Position: 91.3% above the Biotechnology median (#227 of 701)
No single metric tells the full story. See the OSL:ABS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arctic Bioscience AS is a clinical-stage biotechnology company working to develop drug candidates within the areas of autoimmune and inflammatory diseases. It is developing pharmaceutical and commercializing nutraceutical products based on bioactive marine compounds, including lipids essential to maintaining cell membranes. The company's proprietary extraction technology is used to extract membrane fats from marine raw materials, such as herring roe and algae. Geographically, the company operates in Norway, the Americas, Europe, and APAC, with the majority of the revenue derived from the Americas.
55GF Score
Get the complete analysis for OSL:ABS
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSL:ABS has been successfully added to your 
